The Institute of Experimental Medicine (IEM), Academy of Sciences of the Czech Republic
is a partner of the Czech European Advanced Translational Research Infrastructure in Medicine (EATRIS, https://eatris.cz/), which integrate academic translational research and medicine centers to provide optimizing the R&D translational process, from outcomes of basic medical research into clinical research and clinical practice.
IEM offers relevant expertise in ATMP development and translational research in the following research domains:
Regenerative Medicine: Stem Cells and Tissue Engineering
Neurosciences (Neurobiology, Neurophysiology, Neuropathology)
Genetic Ecotoxicology and Cancer Research
UEM is accredited for work with genetically modified organisms (in the first and second risk categories), embryonic stem cells and for the use of experimental animals (mouse, rat, guinea pig). The animal models are developed for the study and treatment of, e.g. spinal cord injury, stroke and cerebral ischemia, healing of skin, bone, cartilage and cornea defects, models of Alzheimer's disease, ALS, and aging. Animal facilities involve conventional or IVC systems.
The IEM manages the Innovation Biomedical Center (IBC) (http://www.iem.cas.cz/en/research/research-centres/innovation-biomedical-centre/) focusing on high-quality basic medical research and, at the same time, having strong ties to innovative biotechnology practice. Since 2008, IBC has been a member of the Czech Science and Technology Parks (www.svtp.cz) and the CzechBio Association. The IBC helps move technologies from the IEM’s laboratories to the marketplace by developing and managing an array of partnerships with the private sector. Currently, the GMP facilities of the IBC are used by the company Bioinova Ltd. specialized in the development of advanced therapy medicinal products based on mesenchymal stromal cells for the needs of clinical trials. Bioinova has a production capacity of aseptic processes (class A/B). The company is a certified manufacturer of aseptic products, and carries out somatic cell therapy according to Good Manufacturing Practice (GMP) standards.
Further on, the IEM founded the Research Center for Cell Therapy and Tissue Repair (http://www.iem.cas.cz/en/research/research-centres/research-center-for-cell-therapy-and-tissue-repair/) financed by the European Regional Development Fund through the Prague Competitiveness Operational Program (2008-2013). The main focus of the Center is the development and preclinical testing of new therapeutic methods using modern therapy products (stem cells, biomaterials) for applications in tissue engineering and regenerative medicine.
Sarka Kubinova, PharmD. PhD.
is a senior researcher, head of the Department of biomaterials and biophysical methods at the IEM (http://www.iem.cas.cz/en/research/departments/department-of-biomaterials-and-biophysical-methods/) and co-ordinator of the Research Center for Cell Therapy and Tissue Repair. Her research focuses on the development of technology of stem cell cultivation and preservation for clinical use and study of therapeutic potential of biomaterials and stem cells in the in vitro and in vivo models. In collaboration with the Institute of Physics AS CR, her department provides research of the effects and safety of low-temperature atmospheric plasmas on biological systems and the development of low-temperature plasma devices for clinical applications. She is an author or co-author of more than 70 publications in impacted journals, 7 book chapters and 2 national patents; h- index 24, > 1400 citations (WOS).